Investment
Features
FeesSafety
Academy
More
Pluang+

Compare REX AI Equity Premium Income ETF (AIPI) vs Medtronic PLC (MDT) Price & Performance

REX AI Equity Premium Income ETFTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

REX AI Equity Premium Income ETF vs Medtronic PLC — how do they compare? REX AI Equity Premium Income ETF trades at $37.45, while Medtronic PLC trades at $90.65 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while REX AI Equity Premium Income ETF pays none, and Medtronic PLC is trading nearer its 52-week high, REX AI Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

AIPIMDT
Sector
Income / Options OverlayHealth
52-Week High
$44.93$105.35
52-Week Low
$32.45$73.75
Market Cap
$116.07B
Enterprise Value
$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

REX AI Equity Premium Income ETF

AIPI trades at $37.45, up 0.29% with a bullish technical signal from moving averages, though oscillators indicate overbought conditions. The ETF maintains an aggressive weekly dividend distribution strategy yielding approximately 35% annually, supported by its AI-focused equity premium income structure. Recent news highlights the fund's transition to weekly distributions and questions about sustainability of high yields.

The high-yield strategy presents income opportunities but faces structural risks including potential NAV erosion if AI market momentum falters. Analyst sentiment remains cautious due to the capped upside from option-writing strategies and dependency on sustained technology sector performance for distribution sustainability.

Medtronic PLC

Medtronic (MDT) trades at $89.99, up 0.65% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent earnings beats, 13.2% net income margin, and positive cash flow trends. Recent product innovations including the Hugo robotic surgery platform and AI surgical tools position MDT for growth. Analyst consensus remains strongly positive with 60% buy ratings and $98.75 price target.

MDT presents a compelling investment case with steady revenue growth, dividend aristocrat status, and technological leadership in medical devices. Key risks include increasing debt levels and competitive pressures from Intuitive Surgical. The stock's current valuation at 24.31 P/E appears reasonable given growth prospects, with upside potential to consensus targets if execution continues.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About REX AI Equity Premium Income ETF

AIPI provides exposure to leading artificial intelligence firms while seeking to generate monthly income. It uses a covered call strategy to capture premiums from the volatility of AI-related stocks.

Read more on AIPI

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT